News

The triple therapy inhaler Trelegy Ellipta (fluticasone furoate, umeclidinium, vilanterol) has received a positive recommendation from the European Medicines Agency (EMA)‘s Committee for Medicinal Products for Human Use (CHMP) to expand its use to a broader population of chronic obstructive pulmonary disease (COPD) patients.

The benefits of Daliresp (roflumilast), an approved chronic obstructive pulmonary disease therapy, may include an anti-inflammatory effect, with the treatment seen in a Phase 3 clinical trial to lower the number of eosinophils — a type of immune cell linked to inflammation — in the lungs of patients with moderate to severe…

AstraZeneca’s triple combination therapy PT010 (budesonide/glycopyrrolate/formoterol fumarate) improved lung function and reduced the rate of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) in a Phase 3 trial, compared with dual combination therapies. Results of the trial were published in the study, “Triple…

A 10-year study has identified several factors that are independent predictors of hospital mortality in critically ill patients with severe chronic obstructive pulmonary disease (COPD). These factors include a patient’s age, the need for mechanical ventilation, and disease severity, the study shows. The research, titled “Factors associated with hospital…

GlaxoSmithKline’s application for approval of mepolizumab as an add-on therapy to reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD) requires more clinical data, the U.S. Food and Drug Administration (FDA) said in a complete response letter. GSK sought approval for mepolizumab as an add-on to inhaled corticosteroid-based maintenance treatments used…

The addition of Verona Pharma’s investigational agent RPL554 to standard short- and long-acting bronchodilators offers greater clinical benefits to patients with chronic obstructive pulmonary disease (COPD). Results of two Phase 2 clinical trials (NCT02542254 and NCT03028142) demonstrated that the RPL554 add-on could enhance the bronchodilation action…

Testosterone replacement therapy can help slow the progression of chronic obstructive pulmonary disease (COPD) in men, a new study shows. Men with COPD tend to experience shortness of breath, leading physicians to prescribe them long-term steroid-based medications. While these medications help treat pulmonary symptoms, they are also associated with…

Electronic cigarettes help reduce exacerbations and improve exercise capacity in patients with chronic obstructive pulmonary disease (COPD) who saw their condition get worse by smoking conventional cigarettes, a new study reports. The study, “Health effects in COPD smokers who switch to electronic cigarettes: a retrospective-prospective 3-year follow-up” was…

Digital health company Adherium recently launched the Hailie solution in the U.S., a technology designed to help patients with asthma and chronic obstructive pulmonary disease (COPD) track their medication usage and better manage their condition. This follows a 510(k) over-the-counter clearance from the U.S. Food and Drug Administration that allows…

AstraZeneca’s Bevespi Aerosphere (glycopyrrolate/formoterol fumarate) has been shown to have similar therapeutic activity in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) as GlaxoSmithKline’s approved therapy Anoro Elipta (umeclidinium/vilanterol). Bevespi Aerosphere combines a fixed dose of two bronchodilators — glycopyrrolate, a…